CURRICULUM VITAE Gerald Louis Andriole, Jr., M.D. Address ...

103. Bhayani, S.B. and Andriole, G.L.: Hormonal Manipulation for Rising PSA after Radical Prostatectomy.
Seminars in Urologic Oncology. 17(3):148-153, 1999.
104. Monk, T.G., Goodnough, L.T., Brecher, M.E., Colberg, J.W., Andriole, G.L., and Catalona, W.J.: A
Prospective Randomized Trial of Three Blood Conservation Strategies for Radical Prostatectomy.
Anesthesiology 91(1):24-33, 1999.
105. Andriole, G.L.: Editorial Comment: Bladder Cancer in the Next Millennium. Journal of Urology
161(1):66, 1999.
106. Krumholtz, JS and Andriole, G.L.: The Surgery of Prostate Cancer: An Update of Contemporary Radical
Prostatectomy and Brachytherapy Series. Seminars in Surgical Oncology. 17(3):213-218, 1999.
107. Roehrborn, C.G., Boyle, P., Bergner, D., et al: Serum Prostate-Specific Antigen and Prostate Volume
Predict Long-Term Changes in Symptoms and Flow Rate: Results of a Four-Year Randomized Trial
Comparing Finasteride Versus Placebo. Urology 54:662-669, 1999.
108. Bruskewitz, R., Girman, C.J., Fowler, J., et al: Effect of Finasteride on Both and Other Health-Related
Quality of Life Aspects Associated with Benign Prostatic Hyperplasia. Urology 54:670-678, 1999.
109. Ornstein, D.K. and Andriole, G.L.: Screening for Prostate Cancer in 1999. AUA Update Series, Lesson
1, Vol. 18.
110. Roehrborn, C.G., McConnell, J., Bonilla, J., Rosenblatt, S., Hudson, P.B., Malek, G.H., Schellhammer,
P.F., Bruskewitz, R., Matsumoto, A.M., Harrison, L.H., Fuselier, H.A., Walsh, P.C., Roy, J., Andriole,
G.L., Resnick, M., and Waldstreicher, J., for the Proscar Long-Term Efficacy and Safety Study: Serum
Prostate Specific Antigen is a Strong Predictor of Future Prostate Growth in Men with Benign Prostatic
Hyperplasia. Journal of Urology 163:13-20, 2000.
111. Carlin, B.I. Andriole, G.L.: Natural History, Skeletal Complications and Management of Bone
Metastases in Patients with Prostate Cancer. Cancer 88(12):2989-2994, 2000.
112. Akakura, K., Akaza, H., Altwein, J., Anderssen, L., Anderstroem, C., Andriole, G.L., and the Prostate
Cancer Trialists’ Collaborative Group (PCTCG): Maximum Androgen Blockade in Advanced Prostate
Cancer: An Overview of the Randomised Trials. Lancet 355:1491-1498, 2000.
113. Fowler, J.E., Gottesman, J.E., Reid, C.F., Andriole, G.L., and Soloway, M.S.: Safety and Efficacy of an
Implantable Leuprolide Delivery System in Patients with Advanced Prostate Cancer. J. Urology 164:730-
734, 2000.
114. Fowler, J.E., Flanagan, M., Gleason, D.M., Klimberg, I.W., Gottesman, J.E., and Sharifi, R. for the
Viadur Study Group: Evaluation of an Implant that Delivers Leuprolide for 1 Year for the Palliative
Treatment of Prostate Cancer. Urology 55:639-642, 2000.
115. Prorok, P.C., Andriole, G.L., Bresalier, R.S., Buys, S.S., Chia, D., Crawford, E.D., Fogel, R., Gelmann,
E.P., Gilbert, F., Hasson, M.A., Hayes, R.B., Johnson, C.C., Mandel, J.S., Oberman, A., O’Brien, B.,
Oken, M.M., Rafla, S., Reding, D., Rutt, W., Weissfeld, J.L., Yokochi, L., Gohagan, J.K., FACE for the
PLCO Project Team: Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening
Trial. Control Clin Trials 21:273S-309S, 2000.
116. Albala, D.M., Turk, T.M.T., Fulmer, B.R., Koleski F., Andriole, G.L., Davis, B.E., Eure, G.R., Kabalin,
J.N., Lingeman, J., Nuzzarello, J., and Sundaram, C.P.: Periurethral Transurethral Microwave
28